{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(2)"],"submitter":["Zhao J"],"pubmed_abstract":["Relapsed and refractory multiple myeloma (RRMM) and B-cell leukemia/lymphoma with extramedullary disease (EMD) have poor prognosis and high mortality, lack of effective therapeutic approaches. We reported for the first time that 6 patients with malignant hematological diseases with EMD received chimeric antigen receptor (CAR)-T treatment combined with pomalidomide, and CAR-T cells were treated with pomalidomide in vitro to determine its killing activity and cytokine secretion. Three patients with RRMM were given B cell maturation antigen (BCMA)-CAR-T therapy. All 3 patients with B-cell leukemia/lymphoma received CD19/22-CAR-T sequential infusion. There were no treatment-related deaths. The maximum overall response rate (ORR) was 100%. Median follow-up was 211.5 days (75-407 days). Three pa"],"journal":["Blood science (Baltimore, Md.)"],"pagination":["e00184"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10906647"],"repository":["biostudies-literature"],"pubmed_title":["Pomalidomide improves the effectiveness of CAR-T treatment in the relapsed and refractory multiple myeloma or B-cell leukemia/lymphoma with extramedullary disease."],"pmcid":["PMC10906647"],"pubmed_authors":["Yang H","He S","Li C","Ma L","Tian W","Ge J","Yao Q","Wei J","Zhao J","Li L","Zhu Q","Ren R"],"additional_accession":[]},"is_claimable":false,"name":"Pomalidomide improves the effectiveness of CAR-T treatment in the relapsed and refractory multiple myeloma or B-cell leukemia/lymphoma with extramedullary disease.","description":"Relapsed and refractory multiple myeloma (RRMM) and B-cell leukemia/lymphoma with extramedullary disease (EMD) have poor prognosis and high mortality, lack of effective therapeutic approaches. We reported for the first time that 6 patients with malignant hematological diseases with EMD received chimeric antigen receptor (CAR)-T treatment combined with pomalidomide, and CAR-T cells were treated with pomalidomide in vitro to determine its killing activity and cytokine secretion. Three patients with RRMM were given B cell maturation antigen (BCMA)-CAR-T therapy. All 3 patients with B-cell leukemia/lymphoma received CD19/22-CAR-T sequential infusion. There were no treatment-related deaths. The maximum overall response rate (ORR) was 100%. Median follow-up was 211.5 days (75-407 days). Three pa","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2025-04-05T11:39:10.523Z","creation":"2025-04-05T11:39:10.523Z"},"accession":"S-EPMC10906647","cross_references":{"pubmed":["38433987"],"doi":["10.1097/BS9.0000000000000184"]}}